Translational Medicine
ISSN: 2161-1025
OPEN ACCESS Freely available online
Commentary

Blood-Based Biomarkers as Clinical Tools for Early Detection and Monitoring of Neurodegenerative Disorders

Mirela Donovan*

Department of Translational Medicine, Eastern Baltic University, Riga, Latvia

DESCRIPTION

Neurodegenerative disorders continue to present significant medical and social challenges because they gradually affect memory, movement, communication, and independent living. Conditions such as Alzheimer's disease, Parkinson's disease, Huntington's disease, and several forms of frontotemporal dementia often develop over many years before recognizable clinical symptoms become evident. During these silent stages, biological changes occur within the nervous system long before noticeable cognitive or physical decline is observed. Identifying these alterations at an earlier stage has become an important objective in translational medicine, which encourages continuous interaction between laboratory investigation and patient care. Among the various scientific developments currently receiving attention, blood-based biomarkers have emerged as valuable clinical tools capable of assisting disease detection, monitoring progression, and evaluating treatment response through relatively simple laboratory procedures.

Historically, neurological diagnosis has depended upon clinical examination, neuropsychological assessment, brain imaging, and analysis of cerebrospinal fluid. Although these methods provide valuable information, several limitations remain. Brain imaging equipment may not be readily available in every healthcare setting, lumbar puncture procedures require specialized personnel, and repeated testing may be inconvenient for many patients. Blood collection, by comparison, represents a familiar clinical procedure performed in hospitals, outpatient clinics, and community healthcare centers throughout the world. This accessibility has encouraged scientists to investigate whether circulating biological molecules accurately reflect changes occurring within the central nervous system.

Blood contains numerous proteins, nucleic acids, metabolites, inflammatory mediators, extracellular vesicles, and cellular fragments released from different tissues throughout the body. Advances in analytical technology have enabled investigators to detect extremely small quantities of molecules previously considered impossible to measure accurately. Some of these circulating components originate directly from damaged nerve cells or supporting glial cells, offering valuable insight into ongoing neurological processes. Careful evaluation of these substances has generated considerable interest because they may provide measurable indicators associated with disease development.

One of the most extensively studied biomarkers involves neurofilament light chain, a structural protein normally present within neurons. When nerve cells experience injury or degeneration, fragments of this protein enter cerebrospinal fluid and eventually appear in circulating blood. Increased concentrations have been observed across multiple neurological conditions, including Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, traumatic brain injury, and several inherited neurological disorders. Although neurofilament light chain does not identify a single disease independently, its concentration frequently reflects the degree of neuronal damage, making it valuable for monitoring disease activity and evaluating clinical progression over time.

Alzheimer's disease has become another major focus of biomarker research. Traditionally, confirmation of disease-associated pathology required specialized brain imaging or examination of cerebrospinal fluid for amyloid-beta and tau proteins. Improvements in laboratory technology have enabled accurate measurement of phosphorylated tau proteins within blood samples. Several investigations have demonstrated that elevated concentrations correlate with characteristic pathological changes occurring inside the brain. Blood measurements therefore provide physicians with additional clinical evidence that may support diagnostic evaluation, especially when combined with cognitive assessment and imaging findings.

Amyloid-beta peptides have also received considerable scientific attention. These protein fragments accumulate abnormally within the brains of individuals affected by Alzheimer's disease. Detecting subtle alterations in circulating amyloid-beta concentrations presents technical challenges because blood contains numerous proteins capable of interfering with laboratory analysis. Continued refinement of analytical methods has improved measurement accuracy, allowing researchers to investigate relationships between circulating amyloid-beta levels

Correspondence to: Mirela Donovan, Department of Translational Medicine, Eastern Baltic University, Riga, Latvia, E-mail: mirela.donovan@ebumed.lv

Received: 24-Feb-2026, Manuscript No. TMCR-26-43668; **Editor assigned:** 26-Feb-2026, PreQC No. TMCR-26-43668 (PQ); **Reviewed:** 12-Mar-2026, QC No. TMCR-26-43668; **Revised:** 19-Mar-2026, Manuscript No. TMCR-26-43668 (R); **Published:** 26-Mar-2026, DOI: 10.35248/2161-1025.26.16.377

Citation: Donovan M (2026). Blood-Based Biomarkers as Clinical Tools for Early Detection and Monitoring of Neurodegenerative Disorders. Trans Med.16:377.

Copyright: © 2026 Donovan M. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

and disease progression. Although interpretation remains complex, combining amyloid-beta with additional biomarkers has strengthened diagnostic performance.

Longitudinal monitoring represents another important clinical application. Repeated blood sampling enables physicians to observe biological changes throughout disease progression without exposing patients to invasive procedures at frequent intervals. Gradual increases or decreases in biomarker concentrations may reflect treatment effectiveness, disease acceleration, or periods of relative stability. Such information allows healthcare professionals to adjust management strategies according to evolving clinical circumstances while maintaining close observation over extended periods.

Population screening has generated considerable scientific discussion. Individuals with a family history of neurodegenerative disease or known genetic susceptibility may benefit from periodic biomarker assessment before symptoms appear. Detecting biological alterations during early stages could encourage lifestyle modification, participation in preventive research programs, and careful neurological monitoring. However, widespread screening requires careful consideration because positive biomarker findings do not necessarily indicate immediate clinical disease. Appropriate counseling and comprehensive medical evaluation remain essential components of responsible implementation.

CONCLUSION

Blood-based biomarkers represent an important direction within translational medicine because they convert laboratory discoveries into clinically useful diagnostic tools capable of supporting earlier recognition, improved monitoring, and more informed therapeutic decision-making. Continued advances in analytical chemistry, molecular biology, computational science, and international collaboration are steadily improving the reliability of these laboratory measurements. As evidence continues to accumulate through carefully designed clinical investigations, blood biomarkers may become routine components of neurological assessment, contributing valuable biological information that complements clinical examination, imaging studies, and patient history while supporting more individualized care for people affected by neurodegenerative disorders.